Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methylnaltrexone→

Methylnaltrexone Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
83387-25-1
Molecular formula
C21H26NO4+
Molecular weight
356.4 g/mol
Drug class
Opioid Antagonist
Mechanism of action
Opioid Antagonists
Indications / reported uses
  • Constipation
  • opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
  • OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care
  • opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e
  • OIC in adult patients with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methylnaltrexone Environmental Risk Assessment (ERA) (the Methylnaltrexone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.